Novartis preps for ASCO data on Tasigna, Afinitor

With the American Society of Clinical Oncology meeting set to begin, the handicapping is in full swing. Novartis ($NVS) is touting its lineup of 160 abstracts, which the company hopes will drive home…
Read the full story: News